Citi analyst Samantha Semenkow raised the firm’s price target on Beam Therapeutics (BEAM) to $68 from $64 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Clear Street sees buying opportunity for Beam Therapeutics after study update
- Beam Therapeutics: BEAM-302’s Differentiated AATD Profile and Accelerated Path Support Buy Rating and $80 Target
- Beam Therapeutics announces safety, efficacy data from BEAM-302 trial
- Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit
- Beam Therapeutics Earnings Call Highlights PKU Pivot